Overview

Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome

Status:
Not yet recruiting

Trial end date:
2022-12-22

Target enrollment:

Participant gender:

Summary

A preliminary assessment of the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Elizabeth Berry-Kravis

Treatments:

5-Hydroxytryptophan
Dihydroergotoxine
Ergoloid Mesylates
Pyridoxal
Pyridoxine
Vitamin B 6